RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 13-24
  • AbbVie profit jumps 7% on strong Humira sales

    AbbVie profit jumps 7% on strong Humira sales
    AbbVie Inc. posted better-than-expected first-quarter earnings on Friday, propelled by another strong quarter of sales of the blockbuster drug Humira. The North Chicago-based pharmaceutical company said Friday that revenue rose 5.4 percent to $4.56...
  • Obamacare enrollment nears 1.4 million in California exchange

    Obamacare enrollment nears 1.4 million in California exchange
    Covered California signed up more than 200,000 consumers for Obamacare coverage after extending its enrollment deadline by two weeks, bringing the statewide total to nearly 1.4 million people. The health insurance exchange gave people until Tuesday to...
  • New drugs provide cure for hepatitis C, research finds

    New drugs provide cure for hepatitis C, research finds
    Twenty-five years after scientists first identified the hepatitis C virus, doctors are declaring victory over an infection that afflicts more than 3 million Americans and kills more of them than HIV. In a series of clinical trial results, a new...
  • Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

    Gilead Sciences' $84,000 price for hepatitis drug is scrutinized
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A....
  • Nasdaq plunges on tech stock sell-off

     Nasdaq plunges on tech stock sell-off
    A plunge in once-soaring technology shares sent Nasdaq into a triple-digit decline and yanked the rest of the stock market down with it. Erstwhile darlings such as Netflix Inc. and Facebook Inc., as well as biotechnology highfliers such as Intercept...
  • U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price

    U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company Thursday, Rep....
  • Prices of new hepatitis C drugs are tough to swallow for insurers

    Prices of new hepatitis C drugs are tough to swallow for insurers
    A pair of new drugs to treat hepatitis C offer a cure for millions of Americans afflicted with the disease — but at a potentially staggering cost to taxpayers and health plans. Until now, therapies for hepatitis C helped only about half of...
  • AIDS deaths worldwide drop as access to drugs improves

    AIDS deaths worldwide drop as access to drugs improves
    LOS ANGELES/GENEVA (Reuters) - Fewer people infected with HIV globally are dying as more of them get access to crucial antiretroviral drugs, particularly in sub-Saharan Africa, the United Nations AIDS program said on Wednesday. The United Nations...
  • WHO endorses use of HIV medicines for prevention

    WHO endorses use of HIV medicines for prevention
    NEW YORK (Reuters) - The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it and suggested that poor and wealthy countries alike set up pilot projects to better...
  • FDA Approves First Ever HIV Prevention Drug

    FDA Approves First Ever HIV Prevention Drug
    LOS ANGELES -- Adults who do not have HIV but are at risk of getting the disease will now be able to take a drug to reduce their chance of getting infected. For the first time, the U.S. Food and Drug Administration approved a drug for this use on Monday....
  • FDA approves Gilead's four-drug HIV treatment

    FDA approves Gilead's four-drug HIV treatment
    (Reuters) - U.S. health regulators on Monday approved Gilead Sciences Inc's four-drug combination pill to treat HIV, the virus that causes AIDS. The four drugs in one pill, which was formerly called the Quad and had been considered one of Gilead's more...
  • Gel Helps Protect Women from HIV Infection

    Gel Helps Protect Women from HIV Infection
    VIENNA, Austria-- A new topical gel has shown promise in helping to protect women from HIV infection, according to a study being presented at the International AIDS Conference in Vienna, Austria. The gel contains the antiretroviral drug tenofovir,...